Inpart Testimonials

“The Huntington’s Disease technology that our TTO manages had been marketed to 30 companies and several CDA-level discussions had been conducted, when last summer two major international pharmaceutical companies both approached us through IN-PART. Ultimately, one of these leads declined further collaboration but still provided useful feedback that, together with feedback collected from previous industry discussions, helped us draft a comprehensive forward-looking project development plan. This development plan helped us in conversations with the second firm, which have led to conducting an evaluative research study to de-risk the technology and assess its potential as a drug. This research will be conducted at the partner site over the next year. We have negotiated an MTA and exclusive option, which the pharma firm can exercise during or after the study. In summary, I believe that IN-PART was instrumental in making the initial contact with both firms, as the respective contacts are located outside of the US and would likely not have been introduced through our traditional technology marketing channels.”

"We have been contacted by via IN-PART. We discussed with them on the phone and concluded that it may be a commercialization/collaboration interest. They asked us to provide several grams of the anti-bacterial materials & active water treatment materials so that they can test them. We provided them the materials and are currently waiting for them to perform the tests.”